|
Index of reports
> Cases with Respiratory Failure ()
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include respiratory failure. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of Next >>
Possible Vincristine side effects in 9 year old male
Reported by a physician from United States on 2012-08-17
Patient: 9 year old male
Reactions: Respiratory Failure, Disseminated Cryptococcosis, Septic Shock
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: weekly
Indication: Acute Lymphocytic Leukaemia
Pegaspargase
Dosage: single dose
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: daily
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in 63 year old male
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-30
Patient: 63 year old male
Reactions: Zygomycosis, Respiratory Failure
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Dosage: for 4 consecutive days
Indication: Diffuse Large B-Cell Lymphoma
Prednisolone
Dosage: at the time of admission
Cyclophosphamide
Dosage: for 5 days
Indication: B-Cell Lymphoma
Prednisolone
Dosage: for 14 days
Indication: B-Cell Lymphoma
Etoposide
Dosage: for 4 consecutive days
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: for 4 consecutive days
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: for 6 days
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Vasopressor Unsp; Amlodipine; Atenolol; Antimycobacterials
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-27
Patient:
Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Epirubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Prednisone and Prednisone
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-20
Patient:
Reactions: Pneumonia, Respiratory Failure
Adverse event resulted in: death
Drug(s) suspected as cause:
Rituximab
Dosage: on day 1
Doxorubicin HCL
Dosage: 75% reduced r-chop
Prednisone
Dosage: 75% reduced r-chop
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 75% reduced r-chop
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: 75% reduced r-chop
Vincristine
Dosage: 75% reduced r-chop
Prednisone
Dosage: on days 1-5
Administration route: Oral
Cyclophosphamide
Dosage: on day 2
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 2, upto a maximum dose of 2 mg
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 2
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-20
Patient:
Reactions: Respiratory Failure
Adverse event resulted in: death
Drug(s) suspected as cause:
Rituximab
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1 for chop and day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1 for chop and day 2 for r-chop upto a maximum dose of 2 mg
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1 for chop and day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in 61 year old male
Reported by a consumer/non-health professional from Germany on 2012-07-13
Patient: 61 year old male
Reactions: Candida Pneumonia, Bronchopneumonia, Febrile Neutropenia, Respiratory Distress, Organising Pneumonia, Respiratory Failure, Interstitial Lung Disease, Pseudomonal Sepsis, Opportunistic Infection, Stenotrophomonas Sepsis, Tracheitis, Septic Shock, Sinusitis
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Campath
Dosage: 30 mg, qd
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-08
Pegfilgrastim
Dosage: 6 mg, qd
Start date: 2010-03-01
End date: 2010-03-01
Cyclophosphamide
Dosage: 1380 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Cyclophosphamide
Dosage: 690 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Doxorubicin HCL
Dosage: 92 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Vincristine
Dosage: 2 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Start date: 2010-02-22
End date: 2010-02-26
Doxorubicin HCL
Dosage: 46 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Posaconazole
Indication: Prophylaxis
Campath
Dosage: 30 mg, qd
Start date: 2010-02-22
End date: 2010-02-23
Vincristine
Dosage: 2 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-11
Pegfilgrastim
Dosage: 3 mg, qd
Indication: T-Cell Lymphoma
Possible Vincristine side effects in male
Reported by a consumer/non-health professional from Germany on 2012-07-10
Patient: male, weighing 60.0 kg (132.0 pounds)
Reactions: Candida Pneumonia, Bronchopneumonia, Tachycardia, Atrial Fibrillation, Febrile Neutropenia, General Physical Health Deterioration, Lactic Acidosis, Respiratory Distress, Respiratory Failure, Skin Lesion, Pseudomonal Sepsis, Tracheitis, Septic Shock
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 92 mg, unk
Indication: Peripheral T-Cell Lymphoma Unspecified
Start date: 2010-01-07
End date: 2010-01-07
Pegfilgrastim
Dosage: 6 mg, once
Start date: 2010-03-01
End date: 2010-03-01
Cyclophosphamide
Dosage: 690 mg, once
Start date: 2010-02-22
End date: 2010-02-22
Campath
Dosage: 30 mg, qd
Indication: Peripheral T-Cell Lymphoma Unspecified
Start date: 2010-01-07
End date: 2010-01-08
Vincristine
Dosage: 2 mg, qd
Start date: 2010-02-22
End date: 2010-02-22
Vasopressin
Dosage: unk
Indication: Blood Pressure Management
Vincristine
Dosage: 2 mg, unk
Indication: Peripheral T-Cell Lymphoma Unspecified
Start date: 2010-01-07
End date: 2010-01-07
Cyclophosphamide
Dosage: 1380 mg, unk
Indication: Peripheral T-Cell Lymphoma Unspecified
Start date: 2010-01-07
End date: 2010-01-07
Doxorubicin HCL
Dosage: 46 mg, once
Start date: 2010-02-22
End date: 2010-02-22
Campath
Dosage: 30 mg, qd
Start date: 2010-02-22
End date: 2010-02-23
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Indication: Peripheral T-Cell Lymphoma Unspecified
Start date: 2010-01-07
End date: 2010-01-11
Prednisone
Dosage: 100 mg, qdx5
Administration route: Oral
Start date: 2010-02-22
End date: 2010-02-26
Pegfilgrastim
Dosage: 3 mg, qd
Indication: Peripheral T-Cell Lymphoma Unspecified
Other drugs received by patient: Zienam; Posaconazole; Taranic; Zienam; Taranic; Candiohermal; Candiohermal
Possible Vincristine side effects in 61 year old male
Reported by a consumer/non-health professional from Germany on 2012-07-10
Patient: 61 year old male
Reactions: Respiratory Failure, Bronchopneumonia, Pseudomonal Sepsis, Febrile Neutropenia, Septic Shock, Tracheitis
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 46 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Vincristine
Dosage: 2 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Cyclophosphamide
Dosage: 1380 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Cyclophosphamide
Dosage: 690 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Pegfilgrastim
Dosage: 3 mg, qd
Indication: T-Cell Lymphoma
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-11
Vincristine
Dosage: 2 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Campath
Dosage: 30 mg, qd
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-08
Posaconazole
Indication: Prophylaxis
Campath
Dosage: 30 mg, qd
Start date: 2010-02-22
End date: 2010-02-23
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Start date: 2010-02-22
End date: 2010-02-26
Pegfilgrastim
Dosage: 6 mg, qd
Start date: 2010-03-01
End date: 2010-03-01
Doxorubicin HCL
Dosage: 92 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Possible Vincristine side effects in 73 year old male
Reported by a physician from Germany on 2012-07-06
Patient: 73 year old male
Reactions: Stenotrophomonas Infection, Febrile Neutropenia, Atrial Fibrillation, Ileus Paralytic, Multi-Organ Failure, Pneumonia Bacterial, Respiratory Failure, Cardiac Failure, Oesophagitis
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1500 mg, unk
Indication: T-Cell Lymphoma
Start date: 2009-06-25
End date: 2009-09-03
Vincristine
Dosage: 1 mg, unk
Indication: T-Cell Lymphoma
Start date: 2009-06-17
End date: 2009-09-03
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Indication: T-Cell Lymphoma
Start date: 2009-06-17
End date: 2009-09-10
Doxorubicin HCL
Dosage: 100 mg, unk
Indication: T-Cell Lymphoma
Start date: 2009-06-25
End date: 2009-09-03
Campath
Dosage: 30 mg, q2w
Indication: T-Cell Lymphoma
Start date: 2009-06-25
End date: 2009-09-04
Pegfilgrastim
Dosage: 6 mg, q2w
Indication: T-Cell Lymphoma
Start date: 2009-06-29
End date: 2009-09-06
Pegfilgrastim
Indication: Prophylaxis
Other drugs received by patient: Ciprofloxacin
Possible Vincristine side effects in
Reported by a physician from United States on 2012-07-05
Patient:
Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Prednisone
Dosage: for 7 days in cycle 1
Indication: Burkitt's Lymphoma
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 2,4 and 6
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: on day 8 from cycle 3 to 7
Prednisone
Dosage: for 7 days in cycle 1
Indication: Burkitt's Leukaemia
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium
Possible Vincristine side effects in
Reported by a physician from Hungary on 2012-07-05
Patient:
Reactions: Pneumonia, Respiratory Failure
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Lymphoma
Prednisone TAB
Indication: Lymphoma
Doxorubicin HCL
Indication: Lymphoma
Vincristine
Indication: Lymphoma
Possible Vincristine side effects in 14 year old female
Reported by a physician from United States on 2012-06-28
Patient: 14 year old female, weighing 60.4 kg (132.9 pounds)
Reactions: Stomatitis, Hypotension, Encephalopathy, Acidosis, Hypercalcaemia, Respiratory Failure, Sepsis, Posterior Reversible Encephalopathy Syndrome, Hypocalcaemia, Enterocolitis, Cardiac Arrest
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Ambisome
Dosage: unk
Indication: Candida Test Positive
Start date: 2012-05-20
Dexamethasone Sodium Phosphate
Dosage: 10 mg/m2, bid or iv on days 1-5 and 15-19
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Mitoxantrone Hydrochloride
Dosage: 10 mg/m2, over 30 minutes on days 1 and 2
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Pegaspargase
Dosage: 2500 iu/m2 over 1 hr on days 3 and 17
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Cefepime
Dosage: unk
Indication: Klebsiella Infection
Start date: 2012-05-10
Vincristine
Dosage: 1.5 mg/m2 cyclic (max 2 mg) over i-5 minutes or infusion via mini bag on days 1, 8, i5 and 22
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Calcium Gluconate
Methotrexate
Dosage: 8-15 mg (age based dosing) it on days 1 (or up to 72 hours prior to day 1) and 8
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Temsirolimus
Dosage: 7.5 mg/m2, over 30 minutes on days i, 8 and 15 (max dose: 15 mg)
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Possible Vincristine side effects in
Reported by a physician from United States on 2012-06-28
Patient:
Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Vomiting, Stomatitis, Dyspnoea, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Respiratory Failure, Diarrhoea, Neurological Symptom, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Rituximab
Dosage: on day 8 from cycle 3 to 7
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Prednisone TAB
Dosage: for 7 days in cycle 1
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Dexamethasone
Dosage: on days 1-5 of cycle 2,4 and 6
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5 of cycle 2,4 and 6
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Lymphoma
Prednisone TAB
Dosage: for 7 days in cycle 1
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Dexamethasone
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Lymphoma
Rituximab
Dosage: on day 8 from cycle 3 to 7
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-25
Patient:
Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Stomatitis, Vomiting, Dyspnoea, Nausea, Gastrointestinal Toxicity, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5 of cycle 2,4 and 6
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: on day 8 from cycle 3 to 7
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Dexamethasone
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Lymphoma
Prednisone TAB
Dosage: for 7 days in cycle 1
Indication: Burkitt's Lymphoma
Prednisone TAB
Dosage: for 7 days in cycle 1
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5 of cycle 2,4 and 6
Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim
Possible Vincristine side effects in 46 year old female
Reported by a individual with unspecified qualification from Germany on 2012-06-21
Patient: 46 year old female
Reactions: Mucosal Inflammation, Respiratory Failure, General Physical Health Deterioration, Haemorrhagic Ascites
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Vincristine
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Indication: non-Hodgkin's Lymphoma
Mabthera
Indication: non-Hodgkin's Lymphoma
Possible Vincristine side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-05
Patient: male, weighing 102.6 kg (225.7 pounds)
Reactions: Cardio-Respiratory Arrest, Respiratory Failure, Anaemia, Troponin I Increased, Thrombocytopenia, Infection
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Methotrexate
Dosage: 1600 mg, cyclic
End date: 2011-07-28
Adriamycin PFS
Dosage: 101 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-05
End date: 2011-07-05
Rituximab
Dosage: 750 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-01
End date: 2011-07-26
Methotrexate
Dosage: 400 mg, cyclic
Indication: Mantle Cell Lymphoma
End date: 2011-07-27
Cytarabine
Dosage: 6 g, cyclic
Indication: Mantle Cell Lymphoma
End date: 2011-07-30
Dexamethasone
Dosage: 40 mg, cyclic
Indication: Mantle Cell Lymphoma
Dexamethasone
Dosage: 20 unk, unk
Administration route: Oral
End date: 2011-07-15
Vincristine
Dosage: 2 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-05
End date: 2011-07-12
Velcade
Dosage: 2.6 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-01
End date: 2011-07-26
Cyclophosphamide
Dosage: 603 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-02
End date: 2011-07-04
Other drugs received by patient: Filgrastim; Ferrous Sulfate TAB; Heparin; Senokot; Triamcinolone Acetonide; Compazine; Ciprofloxacin; Fluconazole; Omeprazole; Mesna; Prevident; Valtrex; Vitamin C / 00008001 /; Methylprednisolone; Periogard; Ultram; Vitamin D
Possible Vincristine side effects in female
Reported by a individual with unspecified qualification from United States on 2012-05-25
Patient: female, weighing 14.9 kg (32.8 pounds)
Reactions: Anaemia, Hyponatraemia, Rash, Pyrexia, Ascites, Abdominal Pain Upper, Abdominal Compartment Syndrome, Respiratory Failure, Pneumonia Herpes Viral, Bone Marrow Failure, Neutropenia, Thrombocytopenia, Cardiac Arrest, Septic Shock, Infection in AN Immunocompromised Host
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: .99 mg
Methotrexate
Dosage: 24.5 mg
Dexamethasone
Dosage: 17.5 ml
Mercaptopurine
Dosage: 460 mg
Possible Vincristine side effects in 46 year old female
Reported by a individual with unspecified qualification from Germany on 2012-05-04
Patient: 46 year old female
Reactions: Mucosal Inflammation, Respiratory Failure, General Physical Health Deterioration, Haemorrhagic Ascites
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Mabthera
Indication: non-Hodgkin's Lymphoma
Doxorubicin Hydrochloride
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Prednisone
Indication: non-Hodgkin's Lymphoma
Vincristine
Indication: non-Hodgkin's Lymphoma
Possible Vincristine side effects in 79 year old female
Reported by a individual with unspecified qualification from Portugal on 2012-04-27
Patient: 79 year old female
Reactions: Pneumonia, Hyperbilirubinaemia, Respiratory Failure, Hepatitis Acute, Urosepsis, General Physical Health Deterioration, Encephalopathy, non-Hodgkin's Lymphoma Recurrent, Hepatitis B
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Vincristine
Indication: non-Hodgkin's Lymphoma
Methotrexate
Indication: non-Hodgkin's Lymphoma
Dexamethasone
Indication: non-Hodgkin's Lymphoma
Rituximab
Indication: non-Hodgkin's Lymphoma
Bleomycin Sulfate
Indication: non-Hodgkin's Lymphoma
Prednisolone
Indication: non-Hodgkin's Lymphoma
Other drugs received by patient: Acarbose; Allopurinol; Omeprazole; Betahistine; Trimetazidine
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-04-18
Patient: male, weighing 102.6 kg (225.7 pounds)
Reactions: Cardio-Respiratory Arrest, Respiratory Failure, Anaemia, Troponin I Increased, Thrombocytopenia, Infection
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Adriamycin PFS
Dosage: 101 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-05
End date: 2011-07-05
Velcade
Dosage: 2.6 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-01
End date: 2011-07-26
Methotrexate
Dosage: 400 mg, cyclic
Indication: Mantle Cell Lymphoma
End date: 2011-07-27
Methotrexate
Dosage: 1600 mg, cyclic
End date: 2011-07-28
Cytarabine
Dosage: 6 g, cyclic
Indication: Mantle Cell Lymphoma
End date: 2011-07-30
Dexamethasone
Dosage: 20 unk, unk
Administration route: Oral
End date: 2011-07-15
Dexamethasone
Dosage: 40 mg, cyclic
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: 603 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-02
End date: 2011-07-04
Vincristine
Dosage: 2 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-05
End date: 2011-07-12
Rituximab
Dosage: 750 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-01
End date: 2011-07-26
Other drugs received by patient: Periogard; Senokot; Compazine; Triamcinolone Acetonide; Valtrex; Fluconazole; Prevident; Ferrous Sulfate TAB; Filgrastim; Ciprofloxacin Hydrochloride; Heparin; Methylprednisolone; Vitamin C / 00008001 /; Vitamin D; Omeprazole; Ultram; Mesna
Possible Vincristine side effects in 59 year old female
Reported by a health professional (non-physician/pharmacist) from Germany on 2012-04-13
Patient: 59 year old female
Reactions: Renal Failure, Respiratory Failure, T-Cell Lymphoma
Adverse event resulted in: death, disablity
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 100 mg, once
Indication: T-Cell Lymphoma
Start date: 2011-09-16
End date: 2011-09-16
Vincristine
Dosage: 2 mg, once
Indication: T-Cell Lymphoma
Start date: 2011-09-16
End date: 2011-09-16
Campath
Dosage: 30 mg, once
Indication: T-Cell Lymphoma
Start date: 2011-09-16
End date: 2011-09-16
Cyclophosphamide
Dosage: 1500 mg, once
Indication: T-Cell Lymphoma
Start date: 2011-09-16
End date: 2011-09-16
Prednisone TAB
Dosage: 100 mg, qdx5
Administration route: Oral
Indication: T-Cell Lymphoma
Start date: 2011-09-16
End date: 2011-09-20
Possible Vincristine side effects in 18 year old male
Reported by a physician from United States on 2012-02-21
Patient: 18 year old male, weighing 72.0 kg (158.4 pounds)
Reactions: Respiratory Failure, Platelet Count Decreased, Herpes Zoster, Klebsiella Sepsis
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Methotrexate
Dosage: ;x1; inth ;x1; inth
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
End date: 2011-12-29
Methotrexate
Dosage: ;x1; inth ;x1; inth
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-01-13
End date: 2012-01-13
Prednisone TAB
Dosage: 20 ug/ m**2; bid; po
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
Vincristine
Dosage: 1.5 mg/ m**2; qw; iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
End date: 2012-01-28
Velcade
Dosage: 1.3 mg/m**2; qd; iv
Indication: Acute Leukaemia
Start date: 2011-12-29
End date: 2011-12-30
Cytarabine
Dosage: ;x1; inth
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
End date: 2011-12-29
Oncaspar
Dosage: 2500 iu/m2; qw; im
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
End date: 2012-01-28
Doxorubicin HCL
Dosage: 60 mg/ m**2; qd; iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
End date: 2011-12-30
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-29
Possible Vincristine side effects in
Reported by a individual with unspecified qualification from Japan on 2012-01-11
Patient:
Reactions: Respiratory Failure, Multiple-Drug Resistance, Pulmonary Alveolar Haemorrhage
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone TAB
Dosage: unk, unknown
Indication: Multiple Myeloma
Lenalidomide
Dosage: 25 mg on days 1-21
Indication: Multiple Myeloma
Prednisolone
Dosage: unk, unknown
Indication: Multiple Myeloma
Thalidomide
Dosage: unk, unknown
Indication: Multiple Myeloma
Melphalan Hydrochloride
Dosage: unk, unknown
Indication: Multiple Myeloma
Dexamethasone TAB
Dosage: 40 mg, (day 1, 8, 15, 22), 4 weekly
Bortezomib
Dosage: unk, unknown
Indication: Multiple Myeloma
Vincristine
Dosage: unk, unknown
Indication: Multiple Myeloma
Doxorubicin HCL
Dosage: unk, unknown
Indication: Multiple Myeloma
Possible Vincristine side effects in 35 year old female
Reported by a physician from Japan on 2011-11-30
Patient: 35 year old female
Reactions: Tumour Lysis Syndrome, Drug Ineffective, Respiratory Failure, Disseminated Intravascular Coagulation, Ventricular Fibrillation, Cardiac Arrest
Adverse event resulted in: death, life threatening event
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Chemotherapy
Methotrexate
Indication: Chemotherapy
Doxorubicin HCL
Indication: Chemotherapy
Morphine
Indication: Bone Pain
Vincristine
Indication: Chemotherapy
Possible Vincristine side effects in 35 year old female
Reported by a physician from Japan on 2011-11-29
Patient: 35 year old female
Reactions: Tumour Lysis Syndrome, Respiratory Failure, Drug Ineffective, Disseminated Intravascular Coagulation, Ventricular Fibrillation, Cardiac Arrest
Adverse event resulted in: death, life threatening event
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: Chemotherapy
Morphine
Indication: Bone Pain
Cyclophosphamide
Indication: Chemotherapy
Vincristine
Indication: Chemotherapy
Methotrexate
Indication: Chemotherapy
Possible Vincristine side effects in 35 year old female
Reported by a individual with unspecified qualification from Japan on 2011-11-25
Patient: 35 year old female
Reactions: Hyperkalaemia, Disseminated Intravascular Coagulation, Pulmonary Alveolar Haemorrhage, Breast Atrophy, Lactic Acidosis, Haemodialysis, Tumour Lysis Syndrome, Respiratory Failure, Ventricular Fibrillation, Cardiac Arrest
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 800 mg/m2
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: 40 mg/m2
Indication: Burkitt's Lymphoma
Vincristine
Dosage: 2 mg/kg
Indication: Burkitt's Lymphoma
Possible Vincristine side effects in 35 year old female
Reported by a health professional (non-physician/pharmacist) from Japan on 2011-11-17
Patient: 35 year old female
Reactions: Tumour Lysis Syndrome, Respiratory Failure, Disseminated Intravascular Coagulation, Ventricular Fibrillation, Cardiac Arrest
Adverse event resulted in: death, life threatening event
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Cyclophosphamide
Indication: Burkitt's Lymphoma
Vincristine
Indication: Burkitt's Lymphoma
Possible Vincristine side effects in 11 year old female
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2011-10-28
Patient: 11 year old female, weighing 35.0 kg (77.0 pounds)
Reactions: Abdominal Pain, Hepatic Function Abnormal, Hypersensitivity, Pain, Rectal Haemorrhage, Extrasystoles, Coagulopathy, Headache, Skin Hyperpigmentation, Caecitis, Erythema, Multi-Organ Failure, Dyspepsia, Chest Pain, Renal Failure Acute, Heart Rate Abnormal, Anuria, Pain in Extremity, Hypotension, Musculoskeletal Pain, Atrial Fibrillation, Rash, Arrhythmia, Acute Lymphocytic Leukaemia, Mucosal Inflammation, Oral Pain, Respiratory Failure, Rash Erythematous, Heart Rate Increased, Electrocardiogram P Wave Abnormal
Adverse event resulted in: death
Drug(s) suspected as cause:
Evoltra
Dosage: 48 mg, qd
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-06-17
End date: 2011-06-21
Dexamethasone
Dosage: 6 mg, bid
Administration route: Oral
Start date: 2011-05-26
End date: 2011-06-08
Dexamethasone
Dosage: 6 mg, bid
Administration route: Oral
Start date: 2011-06-17
End date: 2011-06-23
Cytarabine
Dosage: 30 mg, 1x/w
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-05-11
End date: 2011-06-08
Methotrexate
Dosage: 12 mg, 1x/w
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-05-11
End date: 2011-06-22
Etoposide
Dosage: 120 mg, qd
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-05-12
End date: 2011-05-16
PEG-Asparaginase
Dosage: 1200 iu, q2w
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-05-12
End date: 2011-05-26
Hydrocortisone
Dosage: 12.5 mg, 1x/w
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-05-11
End date: 2011-06-08
Vincristine
Dosage: 1.7 mg, 1x/w
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-05-12
End date: 2011-06-02
Cyclophosphamide
Dosage: 360 mg, qd
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-06-17
End date: 2011-06-21
Dexamethasone
Dosage: 6 mg, bid
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-05-12
End date: 2011-05-18
Etoposide
Dosage: 120 mg, qd
Start date: 2011-06-17
End date: 2011-06-21
Dexamethasone
Dosage: 6 mg, bid
Administration route: Oral
Start date: 2011-07-01
End date: 2011-07-07
Other drugs received by patient: Allopurinol; Cotrim; Levomepromazine; Piperacillin W; Acetaminophen; Ambisome; Acetaminophen; Allopurinol; Ondansetron; Ciprofloxacin; Levomepromazine; Omeprazole; Ondansetron; Penicillin V; Cotrim; Metronidazole
Possible Vincristine side effects in 73 year old male
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2011-10-24
Patient: 73 year old male
Reactions: Pneumonia, Cerebral Infarction, Respiratory Failure, Superior Sagittal Sinus Thrombosis, Blindness
Drug(s) suspected as cause:
Daunorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Prednisolone
Indication: Acute Lymphocytic Leukaemia
Asparaginase
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in 12 year old female
Reported by a health professional (non-physician/pharmacist) from Turkey on 2011-10-12
Patient: 12 year old female
Reactions: Bronchopulmonary Aspergillosis, Electrocardiogram QT Prolonged, White Blood Cell Count Decreased, Hepatic Lesion, Pyrexia, Hypokalaemia, Respiratory Failure, Hypomagnesaemia, Chest Pain, Neutrophil Count Decreased, Cough
Drug(s) suspected as cause:
Voriconazole
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Elspar
Indication: Acute Lymphocytic Leukaemia
Imatinib Mesylate
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Prednisolone
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Magnesium; Ciprofloxacin; Lidocaine; Potassium
Page 1 Next >>
|
